Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 5Gastrointestinal 4NET 2Dermatologic 2CNS 1

Conditions

Brain Neoplasms 1905Glioblastoma 1797Glioma 1130Central Nervous System Neoplasms 599Astrocytoma 594Neuroblastoma 552Gliosarcoma 465Oligodendroglioma 364Neoplasms 312Breast Neoplasms 273Medulloblastoma 272Carcinoma, Non-Small-Cell Lung 227Recurrence 199Sarcoma 184Neoplasm Metastasis 183Melanoma 182Meningioma 177Ependymoma 176Lung Neoplasms 157Lymphoma 134Osteosarcoma 127Meningeal Carcinomatosis 126Neurofibromatosis 1 114Wilms Tumor 111Ovarian Neoplasms 110Diffuse Intrinsic Pontine Glioma 105Precursor Cell Lymphoblastic Leukemia-Lymphoma 103Rhabdomyosarcoma 101Lymphoma, Non-Hodgkin 96Burkitt Lymphoma 89

Interventions

cixutumumab 1Salts 1Octreotide 1Everolimus 1Acetates 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Zollinger-Ellison Syndrome × CNS × Clear all
NCT01204476 2016-07-15

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

National Cancer Institute (NCI)

Phase 1 Completed
27 enrolled
CNSDermatologicEndocrine

Glucagonoma, Insulinoma, Paraganglioma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡